Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

445 ARTÍCULOS , VIENDO DEL 361 AL 375

Combination Drug Therapy for the Management of Alzheimer's Disease

Kabir MT, Uddin MS, Mamun AA, Jeandet P, Aleya L, Mansouri RA, Ashraf GM, Mathew B, Bin-Jumah MN, Abdel-Daim MM.

Int J Mol Sci. 2020 May 5;21(9):3272. doi: 10.3390/ijms21093272.

Editorial: A Is for Amyloid

Selkoe DJ.

J Prev Alzheimers Dis. 2020;7(3):140-141. doi: 10.14283/jpad.2020.27.

Editorial: An Industry Perspective: Future of Anti-Amyloid Trials

Kramer LD.

J Prev Alzheimers Dis. 2020;7(3):142-143. doi: 10.14283/jpad.2020.26.

Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer's Disease

Khan S, Barve KH, Kumar MS.

Curr Neuropharmacol. 2020;18(11):1106-1125. doi: 10.2174/1570159X18666200528142429.

Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks

Guthrie H, Honig LS, Lin H, Sink KM, Blondeau K, Quartino A, Dolton M, Carrasco-Triguero M, Lian Q, Bittner T, Clayton D, Smith J, Ostrowitzki S.

J Alzheimers Dis. 2020;76(3):967-979. doi: 10.3233/JAD-200134.

Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model

Wang S, Mustafa M, Yuede CM, Salazar SV, Kong P, Long H, Ward M, Siddiqui O, Paul R, Gilfillan S, Ibrahim A, Rhinn H, Tassi I, Rosenthal A, Schwabe T, Colonna M.

J Exp Med. 2020 Sep 7;217(9):e20200785. doi: 10.1084/jem.20200785.

Leveraging preclinical models for the development of Alzheimer disease therapeutics

Scearce-Levie K, Sanchez PE, Lewcock JW.

Nat Rev Drug Discov. 2020 Jul;19(7):447-462. doi: 10.1038/s41573-020-0065-9. Epub 2020 Apr 8.

Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer's Disease

Uddin MS, Kabir MT, Rahman MS, Behl T, Jeandet P, Ashraf GM, Najda A, Bin-Jumah MN, El-Seedi HR, Abdel-Daim MM.

Int J Mol Sci. 2020 Aug 14;21(16):5858. doi: 10.3390/ijms21165858.

Sleep as a Novel Biomarker and a Promising Therapeutic Target for Cerebral Small Vessel Disease: A Review Focusing on Alzheimer's Disease and the Blood-Brain Barrier

Semyachkina-Glushkovskaya O, Postnov D, Penzel T, Kurths J.

Int J Mol Sci. 2020 Aug 31;21(17):6293. doi: 10.3390/ijms21176293.

PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients

Wang HY, Pei Z, Lee KC, Lopez-Brignoni E, Nikolov B, Crowley CA, Marsman MR, Barbier R, Friedmann N, Burns LH.

J Prev Alzheimers Dis. 2020;7(4):256-264. doi: 10.14283/jpad.2020.6.

Challenges in demonstrating the value of disease-modifying therapies for Alzheimer's disease

Gustavsson A, Pemberton-Ross P, Gomez Montero M, Hashim M, Thompson R.

Expert Rev Pharmacoecon Outcomes Res. 2020 Dec;20(6):563-570. doi: 10.1080/14737167.2020.1822738. Epub 2020 Sep 20.

β-Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification

Hampel H, Lista S, Vanmechelen E, Zetterberg H, Giorgi FS, Galgani A, Blennow K, Caraci F, Das B, Yan R, Vergallo A; Alzheimer’s Precision Medicine Initiative (APMI).

Alzheimers Res Ther. 2020 Oct 16;12(1):130. doi: 10.1186/s13195-020-00686-3.

Comprehensive Review on Alzheimer's Disease: Causes and Treatment

Breijyeh Z, Karaman R.

Molecules. 2020 Dec 8;25(24):5789. doi: 10.3390/molecules25245789.

Improvements of symptoms of Alzheimer`s disease by inhibition of the angiotensin system

Quitterer U, AbdAlla S.

Pharmacol Res. 2020 Apr;154:104230. doi: 10.1016/j.phrs.2019.04.014. Epub 2019 Apr 13.

Sensory-Based Interventions for Adults with Dementia and Alzheimer's Disease: A Scoping Review

Smith BC, D'Amico M.

Occup Ther Health Care. 2020 Jul;34(3):171-201. doi: 10.1080/07380577.2019.1608488. Epub 2019 May 8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias